FAP and cervical cancer: In this study, a low concentration (4 uM) of anlotinib cannot inhibit the proliferation of NFs and cervical cancer cell lines (Figures 4A, B), but specifically inhibited CAFs activation, α-SMA and FAP expression (Figures 4A, C, D) and cytokines expression and secretion (Figures 6B, C) in vitro, thus suggesting that anlotinib is more potent against CAFs than cervical cancer cells more effectively.